Pharmadrug (TSE:PHRX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PharmaDrug Inc., through its subsidiary Sairiyo Therapeutics, is advancing the clinical development of PD-001, a patented reformulated version of Cepharanthine, aimed at treating a range of viral infectious diseases. After receiving ethics approval in Australia, the company is embarking on a Phase 1 clinical study, with hopes of progressing towards FDA approval. PD-001 is noted for its potential in combating viruses like Ebola and COVID-19, due to its enhanced bioavailability compared to existing formulations.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
